@KUPERWASSERLAB
Cancer diagnoses in England hit record high of more than 1,000 people a dayView quoted post on X
“According to the latest cancer registration statistics, more than 373,000 people were diagnosed with cancer in England in 2024, the highest figure on record. On average, NHS England diagnosed 1,021 people a day with cancer in 2024, up from 972 a day in 2023.”
theguardian.com/society/2026/n…
www.science.org High–temporal resolution profiling reveals distinct immune trajectories following the first and... Blood transcriptome profiling at a high temporal frequency precisely delineates the immune response elicited by mRNA vaccines. She is not "observing potential issues" -- she is strongly implying there IS an issue by saying we are "pretending" there is not.View quoted post on X
And, yes, especially when you have ZERO empirical evidence to link the reported effects to vaccines, in that case it is important to at least propose some plausible mechanism to even lend credence to speculation.
If there is no plausible mechanism and no empirical evidence, then it is truly a "throwing spaghetti against the wall" exercise.
www.biospace.com Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of tumors in patients who have been treated with the spinal muscular atrophy gene... About the intismeran presentation at #ESMO26 $MRNA $MRK
My impression of discussant talk given by Inge Marie Svane of the University of Copenhagen was that she was positive if not overly enthusiastic about INTerpath-001.
"Measured" might be the best, single adjective.
"Brutal" is how an investor in the audience described the tone of her talk to me. (He was short Moderna, so there's that.) I disagree. Brutal is too harsh. If people were expecting Svane to jump for joy, then yes, she did not meet that expectation. To me, she played it mostly straight down the middle.
She took no position on the mRNA vaccine vs neoadjuvant debate. (Slide below)
She noted the lack of intismerna OS benefit, but said the same about neoadjuvant therapy. She also noted greater toxicity associated with neoadjuvant.
For intismeran, Svane also raised the question about what exactly was driving the vaccine’s benefit — was it the specific targeting of the neoantigens, or was it the general immune boost that studies have suggested mRNA vaccines generally provide?View quoted post on X
